Dear All, First, Alan Carr’s Sep 2019 Antibiotic and Antifungal Update (link) is, as usual, required reading (see also this prior blog). Key highlights: He provides an updated by-month sales report from Jan 2016 through Jul 2019 of all products approved since 2009. Sadly, it remains the case that only 4 drugs have sold more than $100m in the
Dear All, I’ve been hearing rumors about this report for a couple of weeks but now it’s out! The US CDC has released their 2019 update to their 2013 Antibiotic Resistance report. Go here for the full report. This report is clearly a labor of love on the part of Team CDC — the graphics, the patient
Dear All, In a marvelous series of tweets, Seema Verma (current Administrator of the US Centers for Medicare and Medicaid Services) today said the following (emphasis is mine): Not-so-fun fact of the day: Most classes of antibiotics prescribed to #Medicare beneficiaries were discovered long ago- before they were even born. #FactFriday #DYK Over time, pathogens have
Dear All: Two links to share today. First, we have a report to the UK House of Commons by their Health and Social Care Committee. This is a well-written summary of the core problem, the economic challenge for pharma, and the varied issues around resistance in human health, animal health, and the environment. Relevant to this community, we
Dear All: Recently announced is a new EU Joint Action on Antimicrobial Resistance (AMR) & Health-Care Associated Infections (HCAI). Its acronym is EU-JAMRAI and the website is https://eu-jamrai.eu/. Joint actions are a common tool for coordinating implementation activities across Europe. EU-JAMRAI actually started in September 2017 and will run for three years but it is really
Dear All: New things continue to appear at a furious pace! Here are 3 excellent opportunities to listen and learn. Even if you can’t be there in person, the first is a webinar and the other two are (in my experience) very likely to be webcast: On 26 June, there will be a webinar sponsored
Dear All: Also appearing today are two valuable opportunities to comment on key global strategy documents. I do hope each of you can make time to look at these materials and consider sending in your thoughts — it really does make a difference when central leadership groups hear from a broad array of stakeholders! First, EMA has
Dear All: Following hard on the heels of yesterday’s note about the 14 June 2018 Duke-Margolis workshop on development of non-traditional products, we now have a notice regarding a 21-22 Aug FDA workshop on that same topic! The meeting will be on FDA’s White Oak Campus from 8.30a-4.30p (21 Aug) and 8.30a-noon (22 Aug). From the notice: “The purpose
Dear All: I hope your summer is going well! Below, three items of interest. See as well several updates to the future meetings list. First,Rep. McCarthy recently introduced the FORWARD (Finding Orphan-disease Remedies with Antifungal Research & Development) Act to the United States House. Seeking to support “endemic orphan fungal disease research, incentivize Valley Fever vaccine development, discover
Dear All: Alan Carr (acarr@needhamco.com, Needham & Company, LLC) writes a superb investment-focused newsletter focused on the antibiotic sector. We all owe him a debt of thanks for his careful analyses. His most recent newsletter (link) is a soups-to-nuts tour that is required reading if you are working in this sector — he covers company status, development program